Omico Omico
  • Industry
  • Researchers
  • Clinicians
  • Patients & Families
  • Advocacy Groups
  • PrOSPeCT
  • Our Programs

        • PROGRAMS

        • Cancer Screening Program (CaSP)
        • Bringing comprehensive genomic profiling to patients with advanced and incurable cancer
        • Molecular Screening and Therapeutics (MoST) study
        • Using the power of genomic technology to characterise molecular changes in a patient's cancer
        • Surveillance study in Multi-Organ Cancer prone syndromes (SMOC+)
        • Investigating and evaluating the surveillance practices used for people at high-risk of multi-organ cancer
        • Genetic Cancer Risk in the Young (RisC) study – Now closed
        • Understanding the genetic variants that contribute to inherited cancer

        • CLINICAL TRIALS

        • Company Studies (C3)
        • Companion Studies (C2)
        • MoST Core Studies (C1)
        • MoST-LLy
        • ASPiRATION
  • Resources & Events
  • About Us
        • About Us
        • Network & Partners
        • Our Board
        • Our Leadership Team
        • Publications
        • Annual Reports
        • Partner Toolkits
  • News
  • Contact
  • Partner Toolkits
  • Resources & Events
  • About Us
    • Network & Partners
    • Our Board
    • Our Leadership Team
    • Publications
    • Annual Reports
  • News
  • Contact
Sign up for newsletter

Ovarian Cancer

edit

By Fidan Rasimoglou • 20 September 2024

comments

comments for this post are closed

  • Privacy Policy
  • Omico is registered not-for-profit company
  • Site Map
Omico Omico